详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Targeting Raf/MEK/ERK pathway in pituitary adenomas

605| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Neurosurg,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Sino German Neurooncol Mol Biol Lab,Wuhan 430030,Peoples R China

出处：

DOI：

ISSN：

关键词： Raf Signalling pathway Pituitary adenomas

摘要：

Pituitary adenomas are the common neoplasms that cause mass effect and/or endocrine dysfunction. Studies in the pathogenesis and functional regulation of pituitary adenomas are mainly focused on the following two topics: (a) the origin of pituitary adenomas and abnormal physical adjustment due to the activation of oncogenes and loss of function for tumour-suppressor genes; and (b) the mechanistic anomalies of the intracellular signal transduction. Among which, the Raf/MEK/ERK signalling has been considered to be one of the major and central pathways in disease aetiology. Raf/MEK/ERK signalling is evolutionarily conserved that controls cellular growth, differentiation and survival. Altered functionality of this signalling pathway has been found to be involved in the development of several types of cancers in humans including pituitary adenomas. This review summarises the roles of Raf/MEK/ERK signalling pathway in pituitary tumourigenesis and highlights the clinical potential of this signalling pathways to be a therapeutic target for intervention and treatment of pituitary adenomas. (C) 2011 Elsevier Ltd. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2011]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

JCR分区：

出版当年[2010]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 7.6 最新[2023版] 7.7 最新五年平均 4.944 出版当年[2010版] 4.776 出版当年五年平均 4.121 出版前一年[2009版] 5.536 出版后一年[2011版]

第一作者：

通讯作者：

通讯机构： [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Neurosurg,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Sino German Neurooncol Mol Biol Lab,Wuhan 430030,Peoples R China [*1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Neurosurg,Jiefang Ave 1095,Wuhan 430030,Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Microscopic Transnasal Transsphenoidal Surgery for Pediatric Pituitary Adenomas [2]Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review [3]Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. [4]Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives [5]Development and Validation of a Prognostic Model for Post-Operative Recurrence of Pituitary Adenomas [6]Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions [7]Clinical features and analysis in 1385 Chinese patients with pituitary adenomas [8]Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas [9]Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas [10]Comparison of Pituitary Adenomas in Elderly and Younger Adults: Clinical Characteristics, Surgical Outcomes, and Prognosis